Cluster randomized trial in smoking cessation with intensive advice in diabetic patients in primary care. ITADI Study

Lydia Roig, Santiago Perez, Gemma Prieto, Carlos Martin, Mamta Advani, Angelina Armengol, Pilar Roura, Josep Maria Manresa, Elena Briones, ITADI Study Group

Abstract

Background: It is a priority to achieve smoking cessation in diabetic smokers, given that this is a group of patients with elevated cardiovascular risk. Furthermore, tobacco has a multiplying effect on micro and macro vascular complications. Smoking abstinence rates increase as the intensity of the intervention, length of the intervention and number and diversity of contacts with the healthcare professional during the intervention increases. However, there are few published studies about smoking cessation in diabetics in primary care, a level of healthcare that plays an essential role in these patients. Therefore, the aim of the present study is to evaluate the effectiveness of an intensive smoking cessation intervention in diabetic patients in primary care.

Methods/design: Cluster randomized trial, controlled and multicentric. Randomization unit: Primary Care Team.

Study population: 546 diabetic smokers older than 14 years of age whose disease is controlled by one of the primary care teams in the study.

Outcome measures: Continuous tobacco abstinence (a person who has not smoked for at least six months and with a CO level of less than 6 ppm measured by a cooximeter) , evolution in the Prochaska and DiClemente's Transtheoretical Model of Change, number of cigarettes/day, length of the visit. Point of assessment: one- year post- inclusion in the study.

Intervention: Brief motivational interview for diabetic smokers at the pre-contemplation and contemplation stage, intensive motivational interview with pharmacotherapy for diabetic smokers in the preparation-action stage and reinforcing intevention in the maintenance stage.

Statistical analysis: A descriptive analysis of all variables will be done, as well as a multilevel logistic regression and a Poisson regression. All analyses will be done with an intention to treatment basis and will be fitted for potential confounding factors and variables of clinical importance. Statistical packages: SPSS15, STATA10 y HLM6.

Discussion: The present study will try to describe the profile of a diabetic smoker who receives the most benefit from an intensive intervention in primary care. The results will be useful for primary care professionals in their usual clinical practice.

Trial registration: Clinical Trials.gov Identifier: NCT00954967.

Figures

Figure 1
Figure 1
ITADI Intervention group study algorithm.

References

    1. Center for Disease Control and Prevention. Annual Smoking- Attributable Mortality, Years of Potential Life Lost, and Productivity Losses--United States, 1997-2001. MMWR Morb Mortal Wlly Rep. 2005;54:625–628.
    1. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004;328:1519. doi: 10.1136/.
    1. Banegas JR, Diez GL, Gonzalez EJ, Villar AF, Rodriguez-Artalejo F. [Recent decrease in smoking-attributable mortality in Spain] Med Clin (Barc) 2005;124:769–771. doi: 10.1157/13075847.
    1. Haire-Joshu D, Glasgow RE, Tibbs TL. Smoking and diabetes. Diabetes Care. 2004;27(Suppl 1):S74–S75.
    1. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28:956–962. doi: 10.2337/diacare.28.4.956.
    1. Fiore MC, Jaen C, Baker T. Public Health Services. Clinical Practice Guideline Rockville, MD: US Department of Health and Human Services Public Health Service 2008; 2008. Treating Tobacco Use and Dependence: 2008 Update. 22-12-2009.
    1. Granollers S. Guies de pràctica clínica, núm.14. Institut Catala de Salut. Barcelona: Institut Català de la Salut; 2009. Detecció i tractament del consum del tabac. 15-10-2009.
    1. Standards of Medical Care in Diabetes-2009. Diabetes Care. 2009;32:S13–S61. doi: 10.2337/dc09-S013.
    1. Spencer L, Pagell F, Hallion ME, Adams TB. Applying the transtheoretical model to tobacco cessation and prevention: a review of literature. Am J Health Promot. 2002;17:7–71.
    1. Riemsma RP, Pattenden J, Bridle C, Sowden AJ, Mather L, Watt IS. Systematic review of the effectiveness of stage based interventions to promote smoking cessation. BMJ. 2003;326:1175–1177. doi: 10.1136/bmj.326.7400.1175.
    1. Ruggiero L, Rossi JS, Prochaska JO, Glasgow RE, de Groot M, Dryfoos JM. Smoking and diabetes: readiness for change and provider advice. Addict Behav. 1999;24:573–578. doi: 10.1016/S0306-4603(98)00086-0.
    1. Ismail AA, Gill GV, Lawton K, Houghton GM, MacFarlane IA. Comparison of questionnaire, breath carbon monoxide and urine cotinine in assessing the smoking habits of Type 2 diabetic patients. Diabet Med. 2000;17:119–123. doi: 10.1046/j.1464-5491.2000.00230.x.
    1. Russell MA, Wilson C, Taylor C, Baker CD. Effect of a general practicioners' advice again smoking. British Medical Journal. 1979;2:231–235. doi: 10.1136/bmj.2.6184.231.
    1. Lancaster T, Stead L, Silagy C, Sowden A. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. BMJ. 2000;321:355–358. doi: 10.1136/bmj.321.7257.355.
    1. Jimenez Ruiz CA, Barrueco FM, Solano RS, Torrecilla GM, Dominguez GF, Diaz-Maroto Munoz JL. [Guidelines for a diagnostic and therapeutic approach to smoking addiction. A consensus report] Arch Bronconeumol. 2003;39:35–41. doi: 10.1157/13042417.
    1. Fiore MC, Bailey WC, Cohen SJ. Public Health Service. US Department of Health and Human Services; 2000. Treating tobacco use and dependence. Clinical Practice Guideline. 6-1-2000.
    1. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56–63. doi: 10.1001/jama.296.1.56.
    1. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47–55. doi: 10.1001/jama.296.1.47.
    1. Smoking cessation services in primary care, pharmacies, local authorities and workplaces, particularly for manual working groups, pregnant women and hard to reach communities. United Kingdom: National Institute for Health and Clinical Excellence; 2008.
    1. Cabezas C, Martin C, Granollers S, Morera C, Ballve JL, Zarza E. Effectiveness of a stepped primary care smoking cessation intervention (ISTAPS study): design of a cluster randomised trial. BMC Public Health. 2009;9:48.
    1. Scemama O, Hamo-Tchatchouang E, Le Faou AL, Altman JJ. Difficulties of smoking cessation in diabetic inpatients benefiting from a systematic consultation to help them to give up smoking. Diabetes Metab. 2006;32:435–441. doi: 10.1016/S1262-3636(07)70301-4.
    1. Persson LG, Hjalmarson A. Smoking cessation in patients with diabetes mellitus: results from a controlled study of an intervention programme in primary healthcare in Sweden. Scand J Prim Health Care. 2006;24:75–80. doi: 10.1080/02813430500439395.
    1. Canga N, De IJ, Vara E, Duaso MJ, Ferrer A, Martinez-Gonzalez MA. Intervention study for smoking cessation in diabetic patients: a randomized controlled trial in both clinical and primary care settings. Diabetes Care. 2000;23:1455–1460. doi: 10.2337/diacare.23.10.1455.
    1. Hokanson JM, Anderson RL, Hennrikus DJ, Lando HA, Kendall DM. Integrated tobacco cessation counseling in a diabetes self-management training program: a randomized trial of diabetes and reduction of tobacco. Diabetes Educ. 2006;32:562–570. doi: 10.1177/0145721706289914.
    1. Reiber GE, King H. Guidelines for the Development of a National. Programme for Diabetes Mellitus. World Health Organization/DBO/. DM/91.1. World Health Organization; 1991.
    1. Cordoba R, Ortega R, Cabezas C, Fores D, Nebot M, Robledo T. Recomendaciones sobre estilo de vida. Atención Primaria. 2001;28:27–34.
    1. Guidelines for smoking cessation. New Zealand National Advisory Committee on Health and Disability. 2002.
    1. Adams G, Gulliford MC, Ukoumunne OC, Eldridge S, Chinn S, Campbell MJ. Patterns of intra-cluster correlation from primary care research to inform study design and analysis. J Clin Epidemiol. 2004;57:785–794. doi: 10.1016/j.jclinepi.2003.12.013.
    1. Parker DR, Evangelou E, Eaton CB. Intraclass correlation coefficients for cluster randomized trials in primary care: the cholesterol education and research trial (CEART) Contemp Clin Trials. 2005;26:260–267. doi: 10.1016/j.cct.2005.01.002.
    1. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JA, Burney PG. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technol Assess. 1999;3:iii–92.
    1. Campbell MK, Elbourne DR, Altman DG. [The CONSORT statement for cluster randomised trials] Med Clin (Barc) 2005;125(Suppl 1):28–31. doi: 10.1016/S0025-7753(05)72206-5.
    1. Cebrìa J, Bosch JM, Prados JA. ¿Cómo podríamos mejorar los resultados de nuestros consejos de salud? Atención Primaria. 2000;7:320–322.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj